We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Simple Blood Sample to Diagnose TBI Severity Could Reduce Need for MRI Scan

By LabMedica International staff writers
Posted on 11 May 2022
Print article
Image: Researchers have identified blood biomarkers that indicate how serious a head trauma is (Photo courtesy of Pexels)
Image: Researchers have identified blood biomarkers that indicate how serious a head trauma is (Photo courtesy of Pexels)

Traumatic brain injury (TBI) is one of the most common neurological diseases worldwide affecting all ages and is commonly caused by a fall, road traffic accident or assault. TBI is divided into three categories ranging from mild to severe, although no reliable methods exist for ruling out acute brain injury. Researchers have now identified biomarkers in the blood that can indicate how serious a head trauma is, enabling a simple blood sample to diagnose TBI severity.

Researchers at Örebro University (Örebro, Sweden) who have been working on a non-surgical procedure to diagnose TBI severity used blood samples collected by EU project CENTER-TBI - the largest study of its kind. The EU project CENTER-TBI currently prospectively collects clinical data including records from 5,400 patients, files of imaging workup as well as blood samples from TBI patients from 60 sites of 18 countries. The overall objective is to apply metabolic profiling of serum in the CENTER-TBI cohort to study the utility of the existing as well as to identify novel biomarkers of TBI which are also predictive of patient outcomes.

Using metabolomics - a chemical analysis method to extract information about thousands of small molecules - the Örebro researchers have identified biomarkers that can be linked to TBI. With the help of these biomarkers, healthcare providers will not only be able to assess the severity of the injury but also predict the patient outcome. Healthcare providers will be able to categorize the injuries more clearly by simply taking a blood sample which is cost-effective, simpler and safer for the patient and eliminates the need for an MRI scan.

Related Links:
Örebro University 

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test
New
Ultrasonic Cleaner
UC 300 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.